hydroxyurea has been researched along with Gastritis in 1 studies
Gastritis: Inflammation of the GASTRIC MUCOSA, a lesion observed in a number of unrelated disorders.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gastritis was graded as severe in three subjects at 40 mg/kg and was considered the dose-limiting toxicity." | 2.78 | A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease. ( Abboud, MR; Ataga, KI; Buchanan, GR; El-Beshlawy, A; Ghalie, RG; Inati, A; Kutlar, A; Perrine, SP; Reid, ME; Smith, H; Taher, AT, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kutlar, A | 1 |
| Reid, ME | 1 |
| Inati, A | 1 |
| Taher, AT | 1 |
| Abboud, MR | 1 |
| El-Beshlawy, A | 1 |
| Buchanan, GR | 1 |
| Smith, H | 1 |
| Ataga, KI | 1 |
| Perrine, SP | 1 |
| Ghalie, RG | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Potential Role of Gum Arabic as Fetal Hemoglobin Agent in Sudanese Sickle Cell Anemia Patients[NCT02467257] | Phase 1/Phase 2 | 47 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
| A Randomized, Open-Label, Multi-Dose Study of HQK-1001 in Subjects With Sickle Cell Disease[NCT01322269] | Phase 2 | 52 participants (Actual) | Interventional | 2011-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for hydroxyurea and Gastritis
| Article | Year |
|---|---|
A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; | 2013 |
A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; | 2013 |
A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; | 2013 |
A dose-escalation phase IIa study of 2,2-dimethylbutyrate (HQK-1001), an oral fetal globin inducer, in sickle cell disease.
Topics: Administration, Oral; Adolescent; Adult; Anemia, Sickle Cell; Antisickling Agents; beta-Thalassemia; | 2013 |